Experimental Gene Therapy Silences Hepatitis B DNA, Aiming to End Viral Rebound

Experimental gene‑therapy CRMA‑1001 can silence hepatitis B virus DNA, offering a chance to stop the infection from rebounding. The hepatitis B virus primarily infects liver cells, where its DNA acts as a template for producing new viral particles. Current drugs target viral proteins but rarely erase the viral DNA, so the virus can return after treatment stops. CRMA‑1001 takes a different route by switching off the viral DNA itself, a strategy that could achieve longer‑lasting control. The approach builds on early DNA chemistry work: in 1904 Henry Wheeler and Treat Johnson created 5‑methylcytosine, a cytosine base with a methyl group, after noting that thymine and uracil differ only by such a group. Their discovery showed that tiny chemical tags can change how DNA behaves, a principle behind modern gene‑silencing tools. By attaching a similar tag to hepatitis B DNA, CRMA‑1001 aims to keep the virus from making new copies. If successful, the therapy could reduce the need for lifelong medication and lower liver‑disease risk. ## Context Hepatitis B affects millions worldwide and is a leading cause of liver cirrhosis and cancer. Traditional treatments keep the virus suppressed but not eliminated, which is why infections often return. Gene‑silencing tactics like CRMA‑1001 represent a shift toward targeting the virus’s genetic blueprint rather than its proteins, promising deeper, more durable cures.